Kewaunee's Net Sales Increase Y/Y, Earnings Decline in Q2
KEQU posts sharp Q2 sales growth, driven by strong backlog and Nu Aire, but earnings decline amid project timing volatility and higher costs.
Kewaunee Upgraded to Outperform on Nu Aire Synergies, Backlog
KEQU earns an upgrade to "Outperform" as Nu Aire integration drives sales growth, margins expand and a record backlog boosts visibility, offsetting tariff risks with proactive inventory strategies.
Kewaunee Scientific Stock Soars 47% After Q4 Earnings Beat Estimates
KEQU posts strong Q4 and FY25 results, driving a 47% stock surge as sales jump and the Nu Aire acquisition boosts growth momentum.
Kewaunee Scientific: Huge Improvement In Operational Outlook (Upgrade To Buy)
Kewaunee Scientific's strong FY2025 results, record backlog, and margin expansion signal a return to growth and improved business predictability. Adjusted EPS actually rose 28% year-over-year, once non-recurring items and acquisition costs are excluded, reflecting core operational strength. A 38% increase in backlog suggests robust revenue growth for FY2026, supporting a bullish outlook and more potential stock upside.
KEQU Reports Y/Y Earnings Decline in Q3 Despite Strong Sales Growth
Kewaunee Scientific's revenues rise 43.6% in Q3, but profits decline due to higher expenses and Nu Aire acquisition costs. Backlog hits $221.6 million.
Kewaunee Scientific: Growth Has Been Priced In After Q2 2025 Report
Kewaunee Scientific manufactures laboratory furniture and equipment, a growing market driven by the need for advancements in healthcare. Since 2022, the company has focused on improving its margins through stop selling directly in some markets where the company had to focus on producing and selling. This has been reflected in the expansion of margins, but growth has been mid-single digit, and I think it can continue like this in the future.
Kewaunee Scientific's Q2 Earnings Rise Y/Y Despite Sales Decline
KEQU reports fiscal Q2 earnings growth, driven by strong domestic demand and strategic acquisition of Nu Aire despite revenue challenges.
Zacks Initiates Coverage of Kewaunee Scientific With Neutral Recommendation
Discover why Zacks rates KEQU as "Neutral," being the first on Wall Street to initiate the coverage of the stock. Explore KEQU's strong order backlog and stable domestic growth amid international challenges and competitive pressures in the laboratory furniture market.
Kewaunee Scientific's Earnings and Sales Decline Y/Y in Q1
Delays in international shipments, especially in India due to customer construction site issues, impact KEQU's Q1 earnings.
Investors With Losses In The Kewaunee Scientific Corporation Urged To Join Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kewaunee Scientific Corporation ("Kewaunee Scientific" or "the Company") (NASDAQ:KEQU) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Shareholders Invited To Participate In The Kewaunee Scientific Corporation Fraud Suit With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kewaunee Scientific Corporation ("Kewaunee Scientific" or "the Company") (NASDAQ:KEQU) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Investors Encouraged To Join The Kewaunee Scientific Corporation Fraud Suit With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kewaunee Scientific Corporation ("Kewaunee Scientific" or "the Company") (NASDAQ:KEQU) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
